Kura Oncology, Inc.: shareholders and insiders

KURANASDAQHealthcare · Pharmaceutical Preparations

Price

$6.91

November 20, 2026Market cap $610M

What Ploutos Investor adds for Kura Oncology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 19, 2026, from their own Form 4 filings.

26 Form 4s

Bought on the market

$3.9M

1 person

Sold on the market

$4.0M

7 people

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan68%
  • The rest32%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $3.9M by 1 person·sold $3.7M by 6 people

  • 2025: no buys, sold $341.8K by 2 people
  • 2026: bought $3.9M by 1 person, sold $3.7M by 6 people
  • Nov 19, 2026Brian T. PowlChief Commercial Officer
    Kind10b5-1
  • Nov 17, 2026Mollie LeoniChief Medical Officer
    Kind10b5-1
  • Nov 17, 2026Brian T. PowlChief Commercial Officer
    Kind10b5-1
  • Nov 17, 2026Kathleen FordChief Operating Officer
    Kind10b5-1
  • Nov 16, 2026Thomas James DoyleSVP, Finance & Accounting
    Kind
  • Nov 16, 2026Mollie LeoniChief Medical Officer
    Kind
  • Nov 16, 2026Brian T. PowlChief Commercial Officer
    Kind
  • Nov 16, 2026Teresa Brophy BairChief Legal Officer
    Kind10b5-1
  • Nov 16, 2026Kathleen FordChief Operating Officer
    Kind10b5-1
  • Nov 16, 2026Troy Edward WilsonPresident and CEO
    Kind
  • Nov 13, 2026Troy Edward WilsonPresident and CEO
    Kind
  • Sep 29, 2026Kathleen FordChief Operating Officer
    Kind10b5-1
  • Sep 29, 2026Mollie LeoniChief Medical Officer
    Kind10b5-1
  • Sep 29, 2026Brian T. PowlChief Commercial Officer
    Kind10b5-1
  • Sep 28, 2026Teresa Brophy BairChief Legal Officer
    Kind10b5-1
  • Sep 28, 2026Kathleen FordChief Operating Officer
    Kind10b5-1
  • Sep 28, 2026Mollie LeoniChief Medical Officer
    Kind
  • Sep 28, 2026Thomas James DoyleSVP, Finance & Accounting
    Kind
  • Sep 28, 2026Brian T. PowlChief Commercial Officer
    Kind
  • Sep 28, 2026Brian T. PowlChief Commercial Officer
    Kind10b5-1
  • Sep 24, 2026Francis BurrowsChief Scientific Officer
    Kind
  • Sep 24, 2026Francis BurrowsChief Scientific Officer
    Kind
  • Aug 24, 2026Troy Edward WilsonPresident and CEO
    Kind
  • Aug 21, 2026Brian T. PowlChief Commercial Officer
    Kind10b5-1
  • Aug 19, 2026Teresa Brophy BairChief Legal Officer
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 4, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by KURA's officers and directors from 2015 up to November 21, 2025, 11 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%Oct 27, 2026 Latest filing
  • Biotechnology Value Fund L Pwith 9 more persons
    Share of class9.99%
  • Montanova Capital, LLCwith 2 more persons
    Share of class9.70%
  • BlackRock, Inc.
    Share of class8.90%
  • State Street
    Share of class5.70%
  • Vanguard Capital Management
    Share of class5.01%
Fell to 5% or less (6)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Armistice Capital, LLC4.23%May 15, 202613G/A
  • The Vanguard Group0.00%Mar 27, 202613G/A
  • EcoR1 Capital, LLC4.80%Aug 14, 202513G/A
  • RA Capital Management, L.P.4.90%May 15, 202513G/A
  • Paradigm BioCapital Advisors LP0.00%Feb 14, 202513G/A
  • Deerfield Mgmt, L.P.0.00%Feb 13, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter+21%
  • AQR Capital
    In the quarter+18%
  • Citadel Advisors (Griffin)
    In the quarter+107%
  • Millennium Mgmt (Englander)
    In the quarter-50%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 16.2% of its shares outstanding were held short, -0.7% since the report before.

Shares held short
14.32M
16.2%
Since the report before14.42M on Sep 30, 2026
-0.7%
8.6
1.67M
More days to cover thanof 4,578 US-listed companies with enough volume
86%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 10.10M
  • Nov 15, 2023: Shares held short 10.87M
  • Nov 30, 2023: Shares held short 11.08M
  • Dec 15, 2023: Shares held short 11.01M
  • Dec 29, 2023: Shares held short 9.26M
  • Jan 12, 2024: Shares held short 9.37M
  • Jan 31, 2024: Shares held short 9.37M
  • Feb 15, 2024: Shares held short 10.51M
  • Feb 29, 2024: Shares held short 11.02M
  • Mar 15, 2024: Shares held short 10.30M
  • Mar 28, 2024: Shares held short 10.41M
  • Apr 15, 2024: Shares held short 10.12M
  • Apr 30, 2024: Shares held short 10.35M
  • May 15, 2024: Shares held short 10.31M
  • May 31, 2024: Shares held short 9.88M
  • Jun 14, 2024: Shares held short 9.84M
  • Jun 28, 2024: Shares held short 8.74M
  • Jul 15, 2024: Shares held short 8.90M
  • Jul 31, 2024: Shares held short 9.26M
  • Aug 15, 2024: Shares held short 10.40M
  • Aug 30, 2024: Shares held short 10.80M
  • Sep 13, 2024: Shares held short 10.75M
  • Sep 30, 2024: Shares held short 10.19M
  • Oct 15, 2024: Shares held short 9.29M
  • Oct 31, 2024: Shares held short 10.80M
  • Nov 15, 2024: Shares held short 11.03M
  • Nov 29, 2024: Shares held short 7.31M
  • Dec 13, 2024: Shares held short 8.89M
  • Dec 31, 2024: Shares held short 10.44M
  • Jan 15, 2025: Shares held short 8.14M
  • Jan 31, 2025: Shares held short 8.08M
  • Feb 14, 2025: Shares held short 9.25M
  • Feb 28, 2025: Shares held short 9.21M
  • Mar 14, 2025: Shares held short 9.02M
  • Mar 31, 2025: Shares held short 8.80M
  • Apr 15, 2025: Shares held short 8.68M
  • Apr 30, 2025: Shares held short 8.28M
  • May 15, 2025: Shares held short 7.95M
  • May 30, 2025: Shares held short 8.36M
  • Jun 13, 2025: Shares held short 7.90M
  • Jun 30, 2025: Shares held short 7.86M
  • Jul 15, 2025: Shares held short 8.41M
  • Jul 31, 2025: Shares held short 7.91M
  • Aug 15, 2025: Shares held short 8.00M
  • Aug 29, 2025: Shares held short 8.41M
  • Sep 15, 2025: Shares held short 10.85M
  • Sep 30, 2025: Shares held short 10.41M
  • Oct 15, 2025: Shares held short 10.61M
  • Oct 31, 2025: Shares held short 8.68M
  • Nov 14, 2025: Shares held short 8.74M
  • Nov 28, 2025: Shares held short 7.99M
  • Dec 15, 2025: Shares held short 8.22M
  • Dec 31, 2025: Shares held short 11.31M
  • Jan 15, 2026: Shares held short 12.31M
  • Jan 30, 2026: Shares held short 13.63M
  • Feb 13, 2026: Shares held short 14.05M
  • Feb 27, 2026: Shares held short 14.58M
  • Mar 13, 2026: Shares held short 14.38M
  • Mar 31, 2026: Shares held short 14.20M
  • Apr 15, 2026: Shares held short 15.01M
  • Apr 30, 2026: Shares held short 15.43M
  • May 15, 2026: Shares held short 15.64M
  • May 29, 2026: Shares held short 13.59M
  • Jun 15, 2026: Shares held short 14.60M
  • Jun 30, 2026: Shares held short 15.09M
  • Jul 15, 2026: Shares held short 13.73M
  • Jul 31, 2026: Shares held short 13.16M
  • Aug 14, 2026: Shares held short 13.12M
  • Aug 31, 2026: Shares held short 13.42M
  • Sep 15, 2026: Shares held short 14.82M
  • Sep 30, 2026: Shares held short 14.42M
  • Oct 15, 2026: Shares held short 14.32M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading52.4% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 52.4% of the shares in the reported trades were short sales, against 64.0% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
52.4%
The 14 beforeOct 14, 2026 – Nov 2, 2026
64.0%
Change
-11.6 pts
Short sales a dayon average, of 1.26M shares
659.2K
More than atof 3,666 US-listed companies, same days
57%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 62.6%
  • Oct 15, 2026: Short sales 64.1%
  • Oct 16, 2026: Short sales 66.6%
  • Oct 19, 2026: Short sales 63.4%
  • Oct 20, 2026: Short sales 66.9%
  • Oct 21, 2026: Short sales 60.9%
  • Oct 22, 2026: Short sales 64.1%
  • Oct 23, 2026: Short sales 79.3%
  • Oct 26, 2026: Short sales 55.3%
  • Oct 27, 2026: Short sales 49.6%
  • Oct 28, 2026: Short sales 57.7%
  • Oct 29, 2026: Short sales 51.9%
  • Oct 30, 2026: Short sales 74.1%
  • Nov 2, 2026: Short sales 73.3%
  • Nov 3, 2026: Short sales 71.1%
  • Nov 4, 2026: Short sales 46.6%
  • Nov 5, 2026: Short sales 53.5%
  • Nov 6, 2026: Short sales 45.6%
  • Nov 9, 2026: Short sales 50.6%
  • Nov 10, 2026: Short sales 48.4%
  • Nov 11, 2026: Short sales 62.2%
  • Nov 12, 2026: Short sales 62.5%
  • Nov 13, 2026: Short sales 53.6%
  • Nov 16, 2026: Short sales 44.9%
  • Nov 17, 2026: Short sales 53.1%
  • Nov 18, 2026: Short sales 55.5%
  • Nov 19, 2026: Short sales 53.8%
  • Nov 20, 2026: Short sales 48.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.18M Insiders' shares2.47% Of the company
  • Troy Edward WilsonPresident and CEO
    Directly935.5K
  • Teresa Brophy BairChief Legal Officer
    Directly178.4K
  • Thomas James DoyleSVP, Finance & Accounting
    Directly138.6K
  • Kathleen FordChief Operating Officer
    Directly132.3K
  • Brian T. PowlChief Commercial Officer
    Directly112.8K
  • Mollie LeoniChief Medical Officer
    Directly99.8K
  • Francis BurrowsChief Scientific Officer
    Directly42.3K
  • Stephen DaleChief Medical Officer
    Directly38.8K
  • Faheem HasnainDirector
    Directly24.0K

A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

18 ETFs holding it0.32% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.32%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.19%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.07%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.06%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.05%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.03%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.03%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.02%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%

18 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

220 Managers, Q2 2026$956M Value of their positions
  • Q3 2025: Managers 201
  • Q4 2025: Managers 217
  • Q1 2026: Managers 224
  • Q2 2026: Managers 220

Institutional investors by quarter

The fund managers holding KURA, quarter by quarter, from Q4 2015 to Q2 2025, 39 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 220 managers held 87.21M shares, worth $956M. During the quarter 28 opened a position, 32 closed one, 89 added and 63 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+9.0%
  • Montanova Capital
    In the quarter
  • Bvf
    In the quarter
  • State Street
    In the quarter+18%
  • Vanguard Capital Management
    In the quarter+3.4%
  • Armistice Capital
    In the quarter-1.6%
  • AQR Capital
    In the quarter+47%
  • Goldman Sachs Group
    In the quarter+58%
  • Geode Capital Management
    In the quarter+9.6%
  • Alethea Capital Management
    In the quarter+42%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Kura Oncology's filings show?

Who buys and sells is one part of Kura Oncology's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about KURA's shareholders

Didn't find what you were looking for?

Ask us
Have KURA's insiders bought or sold?

From Jun 4, 2026 to Nov 19, 2026 Kura Oncology's insiders bought $3.9M and sold $3.2M of shares on the market. 77% of the sales were under set 10b5-1 plans.

Which well-known managers hold KURA?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $40M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.